Sign in
Taking peoplePhase 3

Chronic Pulmonary Aspergillosis and Ambisome Aerosol with Itraconazole

Key facts

Who runs it
Poitiers University Hospital
Where
France37 sites in 1 countryChoose a country to see its sites
Status
Recruiting
Phase
Phase 3
People taking part
224 people, planned
Started
19 Dec 2018
Expected to end
Dec 2029
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • inhaled Ambisome®
  • inhaled placebo
  • Itraconazole
Record updated
20 February 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 32 criteriaShow less

Who can take part

  • All adult patients affected with Chronic Pulmonary Aspergillosis (CPA) "de novo" or in relapse (without any history of resistance to itraconazole) combining the following criteria are eligible:
  • Patient with an Aspergillus bronchopulmonary infection, be it cavitary, fibrotic, necrotizing (SIA/Semi Invasive Aspergillosis) or nodular and documented by compatible thoracic CT-scan images
  • Associated with one of the following criteria:; positive detection of anti-Aspergillus IgG and/or precipitating anti-aspergillus antibodies, according to the positivity threshold of the laboratory performing the technique,; positive direct examination of Aspergillus or positive culture, from bronchopulmonary samples (expectoration or endoscopic aspiration),; revealing aspergillar hyphae/filaments on histological samples
  • Men or women age ≥ 18 years
  • For the women of childbearing age: women having a negative serum pregnancy test, having a contraception highly effective and accepting to pursue it during at least the first 12 months of the study
  • Patient legally free and not subject to any custody, guardianship, tutelage or subordination measures
  • Participants must be affiliated to France's Health Care Regime (" Sécurité Sociale ")
  • Free and informed consent signed by each participating patient

Who cannot take part

  • - Patient presenting a contraindication to itraconazole (including all contraindicated co-administrated medications as listed in the itraconazole SmPc, including notably medications with potential to prolong theQT interval)
  • - Patient presenting a contraindication to voriconazole and posaconazole (including all contraindicated coadministrated medications as listed in the SmPc)
  • - Patient having presented complications related to a previous treatment by nebulised LAmB
  • - Patient received an oral (excepted oral Amphotericin B), parenteral or intra-cavity antifungal treatment within the last 2 months
  • - Concomitant use of one or several of treatments contra-indicated with the experimental or non-experimental treatment
  • - Chronic Pulmonary Aspergillosis with indication for surgical intervention within 6 months from the start
  • - Threatening hemoptysis, with impossibility to defer surgical procedures (but patients contraindicated to surgery may be included after resolution of the hemoptysis)
  • - History of hypersensitivity reaction to liposomal amphotericin B or to itraconazole or to any other constituent
  • - Invasive pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis
  • - Tuberculosis or progressive non-tuberculous mycobacteria
  • - Respiratory infection aggravating the underlying CPA (patient may be included after eradication of infection)
  • - Severe renal failure (clearance <30 ml / min)
  • - Hepatic failure with transaminase and alkaline phosphatase values > 5 times normal
  • - Significant abnormality of the blood cell and platelet counts (at the discretion of the investigator)
  • - Ventricular dysfunction such as congestive cardiac failure or history of congestive cardiac failure or patients with risk(s) factors of cardiac arrhythmia or symptomatic arrhythmia with a prolongation of the corrected QT interval > 450 msec in men and 470 msec in women or treated by medication known to prolong QT interval, or prolongation of the corrected QT interval > 450 msec in men and 470 msec in women
  • - Women at age to procreate and not using highly effective contraception, pregnant or breastfeeding women
  • - Patient affected with single aspergilloma
  • - Intolerance to beta2-agonists
  • - Notion of relapse with isolation of an Aspergillus resistant to itraconazole
  • - Patients with Cystic Fibrosis
  • - Immunocompromised patients
  • - Patient refusing to participate
  • - Protected majors in the meaning of the law, non affiliated persons or with no social security scheme, persons deprived of liberty by a judicial or administrative decision, persons staying in a health or social institution, adults under legal protection, and finally patients in emergencies
  • - Patient in exclusion period following participation in another interventional study evaluating antifungals or medicines

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study compares the therapeutic (clinical and radiological) efficacy of a six-month treatment by itraconazole and nebulised Ambisome® (liposomal amphotericin B = LAmB) versus treatment by itraconazole alone, in non - or mildly - immunocompromised patients affected by Chronic Pulmonary Aspergillosis (single aspergilloma excluded).

Read full original descriptionShow less

• Control arm: Itraconazole 200 mg x 2/day associated with inactive nebulised treatment twice a week during 24 weeks.

• Experimental arm: Itraconazole 200 mg x 2/day associated with nebulised LAmB, at 25 mg twice a week during 24 weeks.

Follow up duration for the patients will be 24 months (12 months minimum) after discontinuation of the treatment being studied.

The 2 groups in the trial

  • Itraconazole & inhaled placeboPlacebo, for comparison

    Itraconazole 200 mg x 2/day associated with inactive nebulised treatment (isotonic saline) twice a week during 24 weeks.

    Treatment: inhaled placebo and Itraconazole

  • Itraconazole & inhaled Ambisome®Treatment being tested

    Itraconazole 200 mg x 2/day associated with inhaled liposomal amphotericin B (Ambisome®) at 25 mg twice a week during 24 weeks

    Treatment: inhaled Ambisome® and Itraconazole

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Therapeutic Efficacy Comparison of a Six-month Treatment by Itraconazole and Nebulised Ambisome® Versus Treatment by Itraconazole Alone in Non- or Mildly- Immunocompromised Patients with Chronic Pulmonary Aspergillosis: a Prospective, Randomized, Single Blind Study, (single Aspergilloma Excluded)
Record updated
20 February 2025